The CXCL12/CXCR4 chemokine signaling axis is a critical pathway involved in neuronal development, migration, neuroinflammation, and neural stem cell biology. This pathway has emerged as an important therapeutic target in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [1]
| Ligand | Aliases | Primary Function | Expression in Brain | [2]
|--------|---------|-------------------|---------------------| [3]
| CXCL12 | SDF-1 (Stromal-Derived Factor-1) | Chemoattraction, cell survival | Neurons, astrocytes, microglia | [4]
| Receptor | Type | Primary Signaling | Brain Expression | [5]
|----------|------|-------------------|------------------| [6]
| CXCR4 | Gαi/o-coupled GPCR | PI3K/Akt, MAPK, PLC-β | High in neurons, neural stem cells | [7]
| CXCR7 | GPCR (β-arrestin biased) | β-arrestin, PI3K/Akt, ERK1/2 | Moderate, often as decoy receptor | [8]
| Effector | Function | Pathway Branch | [9]
|----------|----------|----------------| [10]
| PI3K | Lipid kinase, generates PIP3 | CXCR4/CXCR7 | [11]
| Akt/PKB | Serine/threonine kinase, cell survival | PI3K branch | [12]
| mTOR | Protein synthesis, autophagy regulation | Akt branch | [5:1]
| GSK-3β | Kinase, tau phosphorylation, metabolism | Akt branch | [6:1]
| MAPK/ERK | Mitogen-activated protein kinase | CXCR4 | [7:1]
| PLC-β | Phospholipase, calcium signaling | CXCR4 | [8:1]
CXCL12/CXCR4 signaling plays a crucial role in adult neurogenesis, which is significantly impaired in Alzheimer's disease: [9:1]
The CXCL12/CXCR4 axis modulates neuroinflammatory responses in AD: [13]
The CXCL12/CXCR4 pathway is particularly important for dopaminergic neuron survival: [11:1]
The CXCL12/CXCR4 axis is critically involved in motor neuron development and survival: [12:1]
| Compound | Mechanism | Clinical Status | Application | [14]
|----------|-----------|-----------------|-------------| [15]
| AMD3100 (Plerixafor) | CXCR4 antagonist | FDA-approved for stem cell mobilization | Research in AD, PD, ALS |
| Balixafortide | CXCR4 antagonist | Oncology trials | Preprotection |
| POL632clinical neuro6 | CXCR4 antagonist | Clinical trials | Investigational |
| Compound | Mechanism | Therapeutic Potential |
|---|---|---|
| CXCR7 Agonists | β-arrestin biased signaling | Neuroprotection without inflammation |
| CCX771 | CXCR7 selective antagonist | Modulates inflammatory response |
This section highlights recent publications relevant to this mechanism.
A Sono-Responsive Nanoplatform Integrating STING Activation and CXCR4 Blockade for Synergistic Immunotherapy of Glioblastoma. ↩︎
Adult leptomeningeal vestigial neural crest-derived multipotent cells promote vascular repair after stroke. ↩︎
'CXCR4: A Promising Novel Strategy for Lung Cancer Treatment'. ↩︎
Acupuncture mitigates sciatic neuropathic pain in lumbar disc herniation via inhibiting spinal CXCL12/CXCR4-driven glial activation and neuroinflammation. ↩︎
Miller et al. CXCR4 antagonists in experimental PD (2023). 2023. ↩︎ ↩︎
Sanchez et al. CXCR7 as therapeutic target in PD (2024). 2024. ↩︎ ↩︎
Lieberam et al. CXCL12 in motor neuron development (2023). 2023. ↩︎ ↩︎
Niwa-Kawakita et al. CXCR4 at the neuromuscular junction (2022). 2022. ↩︎ ↩︎
Pujol et al. CXCL12 and axonal regeneration (2024). 2024. ↩︎ ↩︎
[Zhang: [Barcia et al., CXCL12 upregulation in PD substantia nigra (2023)](https://doi.org/10.1016/j.nbd.2023.1:. Li et al., Peripheral immune cell infiltration in PD (2024). 2023. ↩︎
Norden et al. CXCR4 and microglia in ALS (2024). 2024. ↩︎ ↩︎
Gros-Louis et al. CXCL12 dysregulation in SOD1 ALS models (2023). 2023. ↩︎ ↩︎
Azuara et al. Astrocyte-derived CXCL12 in motor neuron support (2023). 2023. ↩︎
Martinez et al. CXCR4 targeting in ALS therapy (2024). 2024. ↩︎
Ferrara et al. Combination approaches for ALS (2023). 2023. ↩︎